---
title: "Zhejiang Conba Pharmaceutical Co.,Ltd. (600572.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600572.SH.md"
symbol: "600572.SH"
name: "Zhejiang Conba Pharmaceutical Co.,Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T08:15:11.646Z"
locales:
  - [en](https://longbridge.com/en/quote/600572.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600572.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600572.SH.md)
---

# Zhejiang Conba Pharmaceutical Co.,Ltd. (600572.SH)

## Company Overview

Zhejiang CONBA Pharmaceutical Co.,Ltd. engages in the research, development, production, and sales of pharmaceuticals and health products in mainland China. It offers medicines, Chinese patent medicines, chemical medicines, Chinese herbal medicine slices, and health products. The company also provides Chinese decoction pieces; over-the-counter medications; healthy consumer products, including nutritional supplements, hygiene products, healthy daily chemicals and food, and other self-care products; and processes agricultural products.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.conbapharm.com](https://www.conbapharm.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: B (0.36)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 25 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4.99% |  |
| Net Profit YoY | -18.86% |  |
| P/B Ratio | 1.50 |  |
| Dividend Ratio | 3.48% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 10877645059.21 |  |
| Revenue | 6706035092.76 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.77% | C |
| Profit Margin | 7.22% | B |
| Gross Margin | 56.74% | B |
| Revenue YoY | 4.99% | C |
| Net Profit YoY | -18.86% | D |
| Total Assets YoY | 2.51% | C |
| Net Assets YoY | 3.53% | C |
| Cash Flow Margin | 209.51% | B |
| OCF YoY | 4.99% | C |
| Turnover | 0.66 | B |
| Gearing Ratio | 27.92% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Zhejiang Conba Pharmaceutical Co.,Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "4.99%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-18.86%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.50",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.48%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "10877645059.21",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "6706035092.76",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.77%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "7.22%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "56.74%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "4.99%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-18.86%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "2.51%",
          "rating": "C"
        },
        {
          "name": "Net Assets YoY",
          "value": "3.53%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "209.51%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "4.99%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.66",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "27.92%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 22.46 | 56/215 | 19.49 | 18.49 | 16.58 |
| PB | 1.50 | 43/215 | 1.74 | 1.66 | 1.59 |
| PS (TTM) | 1.62 | 27/215 | 1.82 | 1.76 | 1.71 |
| Dividend Yield | 3.48% | 24/215 | 3.39% | 3.32% | 3.24% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2024-12-09T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 4.21 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600572.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600572.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600572.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600572.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**